Elutia (ELUT) Competitors $2.01 +0.02 (+1.06%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. CTMX, ALDX, ADCT, BNTC, TNXP, ZYBT, CADL, CAPR, AMRN, and DMACShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include CytomX Therapeutics (CTMX), Aldeyra Therapeutics (ALDX), ADC Therapeutics (ADCT), Benitec Biopharma (BNTC), Tonix Pharmaceuticals (TNXP), Zhengye Biotechnology (ZYBT), Candel Therapeutics (CADL), Capricor Therapeutics (CAPR), Amarin (AMRN), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Its Competitors CytomX Therapeutics Aldeyra Therapeutics ADC Therapeutics Benitec Biopharma Tonix Pharmaceuticals Zhengye Biotechnology Candel Therapeutics Capricor Therapeutics Amarin DiaMedica Therapeutics CytomX Therapeutics (NASDAQ:CTMX) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Which has preferable earnings & valuation, CTMX or ELUT? CytomX Therapeutics has higher revenue and earnings than Elutia. Elutia is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M2.51$31.87M$0.563.75Elutia$24.38M3.50-$53.95M-$1.06-1.90 Do institutionals and insiders hold more shares of CTMX or ELUT? 67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor CTMX or ELUT? In the previous week, CytomX Therapeutics had 1 more articles in the media than Elutia. MarketBeat recorded 3 mentions for CytomX Therapeutics and 2 mentions for Elutia. Elutia's average media sentiment score of 0.92 beat CytomX Therapeutics' score of 0.51 indicating that Elutia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CTMX or ELUT? CytomX Therapeutics currently has a consensus target price of $5.75, suggesting a potential upside of 173.81%. Elutia has a consensus target price of $8.00, suggesting a potential upside of 298.01%. Given Elutia's higher possible upside, analysts clearly believe Elutia is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CTMX or ELUT? CytomX Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Is CTMX or ELUT more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Elutia's net margin of -90.01%. CytomX Therapeutics' return on equity of 158.70% beat Elutia's return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics34.04% 158.70% 36.04% Elutia -90.01%N/A -54.08% SummaryCytomX Therapeutics beats Elutia on 10 of the 15 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.37M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-1.9020.8978.4326.42Price / Sales3.50458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book-1.539.9310.916.06Net Income-$53.95M-$53.38M$3.29B$266.28M7 Day Performance-13.73%0.05%0.01%-0.76%1 Month Performance1.01%7.08%7.06%3.83%1 Year Performance-49.75%11.92%50.09%24.39% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.3089 of 5 stars$2.01+1.0%$8.00+298.0%-51.0%$84.37M$24.38M-1.90180News CoverageGap UpHigh Trading VolumeCTMXCytomX Therapeutics4.2525 of 5 stars$2.00-5.7%$5.75+187.5%+89.3%$349.61M$138.10M3.57170ALDXAldeyra Therapeutics2.5007 of 5 stars$5.77-0.7%$9.50+64.6%+0.7%$347.99MN/A-6.7910News CoverageADCTADC Therapeutics2.7382 of 5 stars$3.09-3.0%$7.75+151.2%+20.3%$347.62M$77.25M-1.96310Short Interest ↓BNTCBenitec Biopharma1.6686 of 5 stars$13.21+1.7%$26.00+96.8%+54.9%$340.99M$80K-8.7520News CoverageTNXPTonix Pharmaceuticals3.3147 of 5 stars$34.59-8.9%$70.00+102.4%+65.0%$332.93M$10.09M-0.8850Gap DownZYBTZhengye BiotechnologyN/A$8.00+14.6%N/AN/A$329.22M$25.53M0.00278News CoverageCADLCandel Therapeutics2.0329 of 5 stars$5.71-4.0%$22.00+285.3%-19.0%$326.63M$120K-8.2860News CoverageAnalyst DowngradeCAPRCapricor Therapeutics2.9009 of 5 stars$6.60-7.0%$22.56+241.8%+43.7%$324.59M$22.27M-4.02101AMRNAmarin0.6407 of 5 stars$15.39-3.7%$12.00-22.0%+20.2%$318.68M$219.36M-4.19360DMACDiaMedica Therapeutics1.7316 of 5 stars$6.00-1.8%$12.33+105.6%+36.2%$315.82MN/A-8.7020Trending NewsAnalyst DowngradeInsider Trade Related Companies and Tools Related Companies CTMX Competitors ALDX Competitors ADCT Competitors BNTC Competitors TNXP Competitors ZYBT Competitors CADL Competitors CAPR Competitors AMRN Competitors DMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
